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Abstract: The sinus node (SN) is the heart’s primary pacemaker and has a unique expression of
pacemaking ion channels and immune cell markers. The role of microribonucleic acids (miRNAs)
in control of ion channels and immune function of the sinus node is not well understood. We have
recently shown that hsa-miR-486-3p downregulates the main pacemaking channel HCN4 in the SN.
In addition, we recently demonstrated that immune cells are significantly more abundant in the
SN compared to the right atrium. The aim of this study was to validate the previously predicted
interactions between miRNAs and mRNAs of key Ca2+ ion channels (involved in peacemaking)
and mRNA of TPSAB1—(a mast cells marker) using luciferase assay. We now show that miR-486
significantly downregulates Cav1.3, Cav3.1, and TPSAB1-mediated luciferase activity, while miR-938
significantly downregulates only TPSAB1-mediated luciferase activity. This makes miR-486-3p a
potential therapeutic target in the treatment of SN dysfunctions.
Keywords: miR-486-3p; miR-938; Cav1.3; Cav3.1; TPSAB1; sinus node; pacemaking channels; mast
cells; cardiovascular diseases
1. Introduction
As part of the cardiac conduction system (CCS), the sinus node (SN) is the primary
pacemaker of the heart and is located at the junction of the superior vena cava and right
atrium. The SN is a crescent-shaped structure that extends along the crista terminalis [1,2].
Compared to the surrounding working myocardium, the SN has distinctive molecular
and functional properties—owing to its unique expression of ion channels and Ca2+-
handling proteins, both responsible for the membrane voltage and Ca2+ clocks—as we
have previously described [1].
Hyperpolarization-activated cyclic nucleotide-gated channels 1 and 4 (HCN1, HCN4)
are the key ion channels responsible for the SN’s myocytes’ diastolic depolarization also
known as the pacemaker potential, with HCN4 being the main isoform that is highly
expressed in human SN [3,4]. The Cav3.1 ion channel carries the T-type calcium current
(ICa,T) at the late diastole phase of the pacemaker potential, and Cav1.3 carries the L-type
calcium current (ICa,L) at the upstroke phase of the action potential [3]. We have previously
shown that these key ion channels are highly expressed in the human SN, compared to the
atrial muscle [1,4]. The SN dysfunction of these ion channels contribute to the development
of SN-related rhythm abnormalities such as bradycardia, tachycardia, sinus arrest, etc. [3,5].
Small noncoding RNA molecules (miRNAs) have been extensively studied and are
known to regulate the post-transcriptional expression of protein-coding genes, through
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inhibition [6] by binding to complimentary 3 prime untranslated region (3′UTR) of their
target messenger-ribonucleic acids (mRNAs). This regulation plays key roles in the devel-
opment of cardiac diseases such as cardiac arrhythmia, hypertrophy, fibrosis, and heart
failure [7–9].
Our previous studies have shown that 18 microRNAs are significantly more experi-
enced, and 48 microRNAs are significantly less expressed in the SN vs. right atrium [1,4].
Among these microRNAs, seven microRNAs (miR-1-3p, miR-30c-5p, miR-133a-3p, miR-
429, miR-4220, miR-486-3p, and miR-938) were predicted to inhibit key pacemaking ion
channels (HCN1, HCN4, Cav1.3, and Cav3.1) [4], key transcription factors (TFs) (TBX3
and TBX18) [4], a mast cell marker (TPSAB1—a tryptase isoenzyme), and macrophage cell
marker CD209 [10], which are significantly more expressed in the SN compared to the right
atrium [10]. We have also shown that miR-486-3p reduces the beating rate of rat SN via
inhibition of HCN4 [4].
To further our understanding of the SN’s pacemaking and immune response function,
the aim of this work was to validate the previously predicted interactions between six
miRNAs and key ion channels, transcription factors, immune cell markers, and collagen
using luciferase assay experiments. A reduction in bioluminescence indicated that the inhi-
bition of miRNA’s target is taking place. Renilla reporter gene is used to normalize values
produced by the luciferase reporter gene. We found that out of the seven microRNAs that
are predicted to inhibit key pacemaking channels and mast cell marker, some microRNAs
did or did not downregulate their predicted targets.
2. Materials and Methods
Main methods are summarized in Figure 1.
2.1. MiRNAs
MiRNA mimics were ordered from the Dharmacon Cherry Pick library (Horizon
Discovery) and arrived in a powder form in a 96-well plate. This was then resuspended
in 1X siRNA buffer (diluted from 5X buffer Dharmacon using RNAse-free water). All
miRNAs were diluted to a final concentration of 5 µM. Plates were spun down, at a speed
of 2000 rpm for 30 s, before adding 20 µL of 1X siRNA buffer to each well and storing at
−20 ◦C. As one of the control experiments, scrambled miRNA (a nonfunctional miRNA)
was used.
2.2. Plasmids
Human Cav1.3 (NCBI Reference Sequence: NM_000720.2; HmiT054373-MT06); HCN4
(NCBI Reference Sequence: NM_005477.2; HmiT088528-MT06); and TBX18 (NCBI Refer-
ence Sequence: NM_001080508.1; HmiT022062-MT06)—3′UTR-containing plasmids were
purchased from GeneCopoeia (Rockville, MD, USA).
Human Cav3.1 (NCBI Reference: NM_001256324.1; HmiT055094-MT06); TPSAB1
(NCBI Reference Sequence: NM_003294.3; HmiT018221-MT06); TBX3 (NCBI Reference Se-
quence: NM_005996.4; HmiT117945-MT06); HCN1 (NCBI Reference Sequence: NM_021072.4;
HmiT117946a-MT06); COL1A1 (NCBI Reference Sequence: NM_000088.4; HmiT127385-
MT06); LZTS1 (NCBI Reference Sequence: NM_001362884.1; HmiT091521-MT06); LBH
(NCBI Reference Sequence: NM_030915.4; HmiT127384-MT06); and HLA-DRA (NCBI Refer-
ence Sequence: 019111.4; HmiT100191-MT06)—3′UTR-containing plasmids were purchased
from LabOmics, UK. The plasmids were delivered in pEZX-MT06 with reporter genes for
firefly luciferase and tracking genes for renilla luciferase, in a 30–50 uL solution. A generic
vector information provided for all plasmids is shown in Figure 2. Further information
regarding predicted interactions between miRNAs and mRNA is shown in in Table 1.
Appl. Sci. 2021, 11, 11366 3 of 12
Appl. Sci. 2021, 11, x FOR PEER REVIEW 2 of 12 
 
Small noncoding RNA molecules (miRNAs) have been extensively studied and are 
known to regulate the post-transcriptional expression of protein-coding genes, through 
inhibition [6] by binding to complimentary 3 prime untranslated region (3′UTR) of their 
target messenger-ribonucleic acids (mRNAs). This regulation plays key roles in the devel-
opment of cardiac diseases such as cardiac arrhythmia, hypertrophy, fibrosis, and heart 
failure [7–9]. 
Our previous studies have shown that 18 microRNAs are significantly more experi-
enced, and 48 microRNAs are significantly less expressed in the SN vs. right atrium [1,4]. 
Among these microRNAs, seven microRNAs (miR-1-3p, miR-30c-5p, miR-133a-3p, miR-
429, miR-4220, miR-486-3p, and miR-938) were predicted to inhibit key pacemaking ion 
channels (HCN1, HCN4, Cav1.3, and Cav3.1) [4], key transcription factors (TFs) (TBX3 and 
TBX18) [4], a mast cell marker (TPSAB1—a tryptase isoenzyme), and macrophage cell 
marker CD209 [10], which are significantly more expressed in the SN compared to the 
right atrium [10]. We have also shown that miR-486-3p reduces the beating rate of rat SN 
via inhibition of HCN4 [4]. 
To further our understanding of the SN’s pacemaking and immune response func-
tion, the aim of this work was to validate the previously predicted interactions between 
six miRNAs and key ion channels, transcription factors, immune cell markers, and colla-
gen using luciferase assay experiments. A reduction in bioluminescence indicated that the 
inhibition of miRNA’s target is taking place. Renilla reporter gene is used to normalize 
values produced by the luciferase reporter gene. We found that out of the seven mi-
croRNAs that are predicted to inhibit key pacemaking channels and mast cell marker, 
some microRNAs did or did not downregulate their predicted targets. 
2. Materials and Methods 
Main methods are summarized in Figure 1. 
 
Figure 1. Summary of main methods. H9C2, a rat cardiomyoblast cell line; OptiMEM (Life Technologies, Inc., 
Gaithersburg, MD, USA), minimal essential medium; and miRNA, microribonucleic acid. Created with BioRender.com. 
2.1. MiRNAs 
Figure 1. Summary of main ds. H9C2, a rat cardiomyoblast cell line; OptiMEM (Life Technologies, Inc., Gaithersburg,
MD, USA), minimal essential medium; and miRNA, microribonucleic acid. Created with BioRend r.com.
Appl. Sci. 2021, 11, x FOR PEER REVIEW 3 of 12 
 
MiRNA mimics were ordered from the Dharmacon Cherry Pick library (Horizon Dis-
covery) and arrive  in a powder form in a 96-well plate. This was then resuspended in 1X 
siRNA buffer (diluted from 5X buffer Dharmacon using RNAse-free water). All miRNAs 
were diluted to a final concentration of 5 µM. Plates were spun down, at a speed of 2000 
rpm for 30 s, before adding 20 µL of 1X siRNA buffer to each well and storing at −20 °C. 
As one of the control experiments, scrambled miRNA (a nonfunctional miRNA) was used. 
2.2. Plasmids 
Human Cav1.3 (NCBI Reference Sequence: NM_000720.2; HmiT054373-MT06); 
HCN4 (NCBI Reference Sequence: NM_005477.2; HmiT088528-MT06); and TBX18 (NCBI 
Reference Sequence: NM_001080508.1; HmiT022062-MT06)—3′UTR-containing plasmids 
were purchased from GeneCopoeia (Rockville, MD, USA). 
Human Cav3.1 (NCBI Reference: NM_001256324.1; HmiT055094-MT06); TPSAB1 
(NCBI Reference Sequence: NM_003294.3; HmiT018221-MT06); TBX3 (NCBI Reference 
Sequence: NM_005996.4; HmiT117945-MT06); HCN1 (NCBI Reference Sequence: 
NM_021072.4; HmiT117946a-MT06); COL1A1 (NCBI Reference Sequence: NM_000088.4; 
HmiT127385-MT06); LZTS1 (NCBI Reference Sequence: NM_001362884.1; HmiT091521-
MT06); LBH (NCBI Reference Sequence: NM_030915.4; HmiT127384-MT06); and HLA-
DRA (NCBI Reference Sequence: 019111.4; HmiT100191-MT06)—3′UTR-containing plas-
mids were purchased from LabOmics, UK. The plasmids were delivered in pEZX-MT06 
with reporter genes for firefly luciferase and tracking genes for renilla luciferase, in a 30–
50 uL solution. A generic vector information provided for all plasmids is shown in Figure 
2. Further information regarding predicted interactions between miRNAs and mRNA is 
show  in in Table 1. 
 
Figure 2. Generic vector map for all human plasmids used. SV40, Simian Virus 40 promoter; CMV, 
cytomegalovirus; hLuc, Firefly luciferase reporter gene. Modified from GeneCopoeia (Rockville, 
MD, USA) and LabOmics, Nivelles, Belgium. 
Table 1. Predicted microRNA-mRNA interactions. MicroRNA expression data are based on our 
previous studies [4,10]. Significant change in the expression of mRNA and microRNA is classed as 
p ≤ 0.05. Red represents significantly more expressed mRNA in the SN vs. right atrium. Green rep-
resents significantly less expressed microRNA in the SN vs. right atrium. HCN1, HCN4, Cav1.3, and 
Cav3.1 are pacemaking ion channels (see text for details); LZTS1, LBH, TBX3, and TBX18 are tran-
scription factors; COL1A1 is a collagen marker; TPSAB1 is a mast cell marker; HLA-DRA is histo-
compatibility complex marker; and CD209 is a macrophage cell marker. N = no; Y = yes; Hsa = ho-
mosapien. 
Figure 2. Generic vector map for all human plasmids used. SV40, Simian Virus 40 promoter; CMV,
cytomegalovirus; hLu , Firefly luciferase reporter gene. Modified from GeneCopoeia (Rockville, MD,
USA) and LabOmics, Nivelles, Belgium.
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2.3. Plasmid Amplification
In total, 1 µL of plasmid was taken up in 20 µL of supercompetent cells (XL1-Blue,
Agilent Technologies) and placed on ice for 3 min before heat-shocking for 30 s. The solution
was placed on ice again before spreading 21 µL solution on an agar gel plate (containing
carbenicillin) and incubating at 37 ◦C overnight. Then, a single bacterial colony transfected
with the plasmid was added to a solution containing 3 mL sterile LB medium and 3 µL
carbenicillin (100 µg/µL) overnight at 37 ◦C, shaking at a speed of 120 rpm. Following this,
1 mL of the resulting culture was mixed with a solution containing 200 mL LB medium and
200 µL carbenicillin (100 µg/µL) overnight at 37 ◦C, shaking at a speed of 120 rpm. The
remaining 2 mL of culture was added to 200 µL 50% glycerol and stored at−80 ◦C for future
use. The next day, the plasmid DNA was extracted and purified using Purelink Plasmid
Kit (Thermo Fisher Scientific, Altrincham, UK), according to manufacturer’s protocol.
Concentration of plasmids was determined using a NanoDrop ND-1000 spectrophotometer
(ThermoScientific, Altrincham, UK). The plasmid concentrations ranged between 0.3 and
2.3 µg/ µL.
Table 1. Predicted microRNA-mRNA interactions. MicroRNA expression data are based on our previous studies [4,10].
Significant change in the expression of mRNA and microRNA is classed as p ≤ 0.05. Red represents significantly more
expressed mRNA in the SN vs. right atrium. Green represents significantly less expressed microRNA in the SN vs. right
atrium. HCN1, HCN4, Cav1.3, and Cav3.1 are pacemaking ion channels (see text for details); LZTS1, LBH, TBX3, and TBX18
are transcription factors; COL1A1 is a collagen marker; TPSAB1 is a mast cell marker; HLA-DRA is histocompatibility
complex marker; and CD209 is a macrophage cell marker. N = no; Y = yes; Hsa = homosapien.


























Hsa-miR-429 UAAUACUGUCUGGUAAAACCGU TBX18 1
Hsa-miR-422a ACUGGACUUAGGGUCAGAAGGC TBX3 1
2.4. Luciferase Reporter Gene Assay
Rat cardiac H9C2 cells (cell line purchased from ATCC, LGC Limited, Middlesex,
UK) were maintained in DMEM (Life Technologies, Inc., Gaithersburg, MD, USA) contain-
ing 10% feline bovine serum (Life Technologies, Inc., Gaithersburg, MD), 1% penicillin-
streptomycin (Life Technologies, Inc., Gaithersburg, MD), and 1% nonessential amino acids
(Thermo Fisher Scientific, Altrincham, UK). At day 1, cells were plated in 48-well plates
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at a density of 50,000 cells in a volume of 250 µL of media for 24 h. Following this, the
medium was removed and replaced with 225 µL of fresh medium. Cells were transfected
with 0.25 µg plasmid (from a 1 µg/µL stock solution) with 1.25 µL miRNA (from a 5 µM
stock) in 11 µL of optiMEM (Life Technologies, Inc., Gaithersburg, MD). Lipofectamine
2000 (ThermoScientific, Altrincham, UK) was diluted in optiMEM (0.75 µL lipofectamine
2000 with 11.75 µL optiMEM). Then, the diluted lipofectamine 2000, diluted miRNA, and
diluted plasmid were mixed (see Figure 1 for details) and allowed to incubate for 5 min at
room temperature before adding to the cells in each well. The cells were then incubated at
37 ◦C and 5% CO2 for 24 h before luciferase activity was measured.
Following this, renilla and luciferase substrate and buffers (Promega) were thawed
at room temperature. Here, 1X cell culture lysis was prepared from 5X cell culture lysis
reagent (Promega), using milliQ water to dilute. Medium was aspirated from the cells
before washing with PBS, and then 50 µL lysis buffer was added and placed on a rocker
for 20–25 min. In addition, 10 µL of each lysate was added into a 96-well plate in dupli-
cate for both renilla and luciferase assay readings. A GloMax Luminometer (Promega,
Southampton, UK) was set up to inject 50 µL of either luciferase (from injector pump 1) or
renilla (from injector pump 2) per well. Luciferase assay activity was normalized to renilla
assay activity to obtain a ratio than was then inputted in GraphPad Prism 8. Batches of
experiments ranged between 3 and 6.
2.5. Statistical Analysis
In Tables 2 and 3 and Figures 3–5 mean ± SEM values are shown. All statistical
analysis was carried out using GraphPad Prism 8. Significant differences were identified
using unpaired t test. Significant difference was assumed at p ≤ 0.05.
Table 2. Nonsignificant downregulation of hsa-mRNAs by hsa-miRNAs in H9C2 cells, observed following luciferase assay
experiments. Mean ± SEM values are shown. Red represents significantly more expressed mRNA in the SN vs. right atrium



















HCN1 0.789 ± 0.205 0.686 ± 0.211 - -
HCN4 0.558 ± 0.144 0.422 ± 0.103 - -
TBX3 0.686 ± 0.244 0.586 ± 0.189 - -
Hsa-miR-30c-5p












HCN1 0.554 ± 0.157 0.686 ± 0.211 0.593 ± 0.344 0.580 ± 0.313
LZTS1 0.326 ± 0.178 0.556 ± 0.178 0.707 ± 0.398 0.589 ± 0.310
LBH 0.343 ± 0.142 0.604 ± 0.228 0.7065 ± 0.398 0.589 ± 0.310
HLA-DRA 0.672 ± 0.228 0.944 ± 0.359 0.593 ± 0.344 0.580 ± 0.313
Hsa-miR-133a-3p












LBH 0.276 ± 0.109 0.575 ± 0.190 0.081 ± 0.035 0.093 ± 0.024
Hsa-miR-429 TBX18 0.593 ± 0.048 0.558 ± 0.229 - -
Hsa-miR-422a TBX3 0.512 ± 0.171 0.586 ± 0.179 - -
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Table 3. Significant downregulation of hsa-mRNAs by hsa-miRNAs in H9C2 cells, observed following luciferase assay
experiments. Mean ± SEM values are shown. Red represents significantly more expressed mRNA in the SN vs. right
atrium, whereas green represents significantly less expressed miRNA in the SN vs. right atrium, as shown in our previous

















Hsa-miR-486-3p Cav3.1 0.511 ± 0.111 1.188 ± 0.281 0.596 ± 0.344 0.567 ± 0.318
Cav1.3 0.211 ± 0.039 0.449 ± 0.019 0.057 ± 0.020 0.083 ± 0.026
TPSAB1 1.049 ± 0.256 2.240 ± 0.032 0.593 ± 0.344 0.580 ± 0.313
Hsa-miR-938 Cav1.3 0.159 ± 0.025 0.449 ± 0.019 0.074 ± 0.020 0.087 ± 0.020
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Figure 3. Luciferase bioluminescence after transfection of H9C2 cells with hsa-miR-486-3p and plasmids. Bioluminescence 
was recorded 24 h after transfecting H9C2 cells with 0.25 µg of (A) Cav1.3′- or (B) Cav3.1—3′-untranslated region-contain-
ing plasmid and 1.25 µL hsa-miR-486-3p or scrambled hsa-miRNA. Two control groups did not include the luciferase 
reporter gene, and cells were transfected with only hsa-miR-486-3p or remained untransfected (i.e., contained an equiva-
lent volume of culture medium to replace the hsa-miRNAs or 3′-untranslated region-containing plasmid). Data are shown 
as mean ± SEM (n = 3 batches of experiments were plotted for Cav1.3; n = 6 batches of experiments were plotted for Cav3.1; 
* p ≤ 0.05, ** p ≤ 0.005). 
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Two control groups did not include the luciferase reporter gene, and cells were transfected with 
only hsa-miR-938 or remained untransfected (i.e., contained an equivalent volume of culture me-
dium to replace the miRNAs or Cav1.3). Data are shown as mean ± SEM shown (n = 3 batches of 
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Figure 5. Luciferase bioluminescence after transfection of H9C2 cells with hsa-miR-486-3p and
hsa-TPSAB1. Bioluminescence was recorded 24 h after transfecting H9C2 cells with 0.25 µg of
hsa-TPSAB1 3′-untranslated region-containing plasmid and 1.25 µL has-miR-486-3p or scrambled
miRNA. Two control groups did not include the luciferase reporter gene, and cells were transfected
with only hsa-miR-486-3 or remained untransfected (i.e., contained an equivalent volume of culture
medium to replace the iRNAs or hsa-TPSAB1). Data are shown as ean SEM shown (n = 3
batches of experiments; * p ≤ 0.05).
2.6. Binding Sites Prediction
Genome (https://genome.ucsc.edu acc ssed on 25 November 2021) was used to
obtain the 3′UTR sequ nce for the target mRNAs. MirBase (https://www.mirbase.org
accessed on 25 November 2021) was used to obtain the sequence for the microRNAs. The
microRNA sequence and the 3′UTR sequence for their target mRNA were uploaded into
RNA22 v2 (https://cm.jefferson.edu/rna22/interactive/ accessed on 25 November 2021)
or TargetScan Human (http://www.targetscan.org/vert_72/ accessed on 25 November
2021) in order to predict the number of binding sites on the mRNAs for their corresponding
microRNAs and identify predicted binding sites (Table 1).
3. Results
Out of the 12 hsa-mRNAs that had been predicted to be inhibited by their respective
has-miRNAs, we did not observe a significant decrease in luciferase activity with eight hsa-
mRNAs and their respective hsa-miRNAs (Table 2). However, we observed a significant
decrease in luciferase activity with four hsa-mRNAs and their respective hsa-miRNAs
(Table 3, Figures 3–5), suggesting the presence of interaction between the hsa-mRNAs and
hsa-miRNAs. Therefore, we can assume a reduction in the expression of the genes and
proteins encoded by these genes, based on these observed interactions.
3.1. Hsa-miR-486-3p Significantly Downregulates Hsa-Cav1.3
Hsa-Cav1.3 is predicted to have six binding sites for hsa-miR-486-3p (Table 1). Hsa-
Cav1.3-mediated luciferase activity was significantly reduced by hsa-miR-486-3p when
compared to cells transfected with hsa-Cav1.3 and scrambled miR, hsa- iR-486-3p only, or
negative control cells (culture media only) (Table 2 and Figure 3).
3.2. Hsa-miR-486-3p Significantly Downregulates Hsa-Cav3.1
Hsa-Cav3.1 is predicted to have one binding site for hsa-miR-486-3p (Table 1). Hsa-
Cav3.1-mediated luciferase activity was significan ly reduced by hsa miR-486-3p, when
compared to cells transfected with hsa-Cav3.1 and scrambled miR, - i - - only, or
negative control cells (culture media only) (Table 2 and Figure 3).
3.3. Hsa-miR-938 Significantly Downregulates Hsa-Cav1.3
Hsa-Cav1.3 is predicted t have nine binding sites for hsa-miR-938 (Table 1). Hsa-
Cav1.3-mediated luciferase activity was significantly reduced by hsa-miR-938, when com-
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pared to cells transfected with hsa -Cav1.3 and scrambled miR, hsa-miR-938 only, or
negative control cells (culture media only) (Table 2 and Figure 4).
3.4. Hsa-miR-486-3p Significantly Downregulates Hsa-TPSAB1
Hsa-TPSAB1 is a marker for mast cells, involved in immune system regulation, and is
predicted to have two binding sites for hsa-miR-486-3p (Table 1). Hsa-TPSAB1-mediated
luciferase activity was significantly reduced by hsa-miR-486-3p, when compared to cells
transfected with hsa-TPSAB1 and scrambled miR, hsa-miR-486-3p only, or negative control
cells (culture media only) (Table 2 and Figure 5).
4. Discussion
Following our previously predicted interactions between key hsa-miRNAs and key
hsa-mRNAs [4,10], it was important for us to experimentally verify these predictions. It
should be noted that the experimental validation of miRNA-mRNA interaction is still a
challenging feat. The reason why some predicted microRNA-mRNA interactions have
been confirmed (through observations of significantly reduced bioluminescence/luciferase
activity) and some interactions could not be confirmed could be due to several factors such
as: thermodynamic stability and binding site accessibility—as recently reviewed by Riolo
et. al., 2021 [11].
The current study focuses on two microRNAs (hsa-miR-486-3p and hsa-miR-938) that
significantly reduces the luciferase of the mRNAs encoding for Ca2+ ion channels (Cav1.3
and Cav3.1) and a mast cell marker (TPSAB1) in H9C2 cells (Table 3). This suggests that
an interaction between these mRNAs and their respective microRNAs is taking place;
therefore, this could result in a reduction in expression of Cav1.3, Cav3.1, and TPSAB1.
In our previous study, we have shown that the direct binding of hsa-miR-486-3p
to hsa-HCN4 significantly reduces HCN4-mediated luciferase activity and reduces the
beating rate in the rat SN preparations [4]. We now provide evidence that hsa-miR-486-3p
also significantly downregulates the luciferase activity of mRNAs encoding hsa-Cav1.3,
hsa-Cav3.1, and hsa-TPSAB1 (Figures 3–5).
4.1. Hsa-miR-486-3p
Hsa-miR-486-3p is less expressed in the SN, which explains why the pacemaking
ion channels and other related transcripts are more expressed in this specialized tissue of
the heart [4]. In human SN during heart failure, hsa-miR-486-3p is upregulated [12]. The
other predicted targets for hsa-miR-486-3p are hsa-Cav1.3, hsa-Cav3.1, hsa-TPSAB1, hsa-
HCN1, hsa-HCN4, LZTS1, LBH, HLA-DRA, and TBX18 [4,10]—all of which we explored
through luciferase assay experiments. Interestingly, we observed that hsa-miR-486-3p
can significantly reduce the luciferase activity of three key target mRNAs (hsa-Cav1.3,
hsa-Cav3.1, and hsa-TPSAB1) (Figures 3 and 5). In acute myocardial infarction patients,
their serum hsa-miR-486-3p levels is increased [13,14]. The expression of hsa-miR-486-3p is
also elevated during ventricular hypertrophy [15] and in patients with congenital heart
diseases [16]. Not only does hsa-miR-486-3p inhibit hsa-TPAB1 (a mast cell marker), it
also inhibits hsa-CD209 (a macrophage marker) [10]. We have pilot data that show a trend
toward hsa-miR-486-3p inhibiting hsa-CD209 (data not shown). Hulsmans et. al. (2017)
noticed a high expression of immune cells in the atrioventricular node (AV) of mice [17].
They also observed AV block and bradycardia in mice that had reduced macrophage
expression [17]. Incidentally, severe COVID-19 patients suffer from bradycardia [18,19],
and the expression of hsa-miR-486-3p in their blood is increased due to an immune response
to the virus [20].
Based on our studies and many other studies described above, hsa-miR-486-3p can be
a principal therapeutic target in the treatment of cardiac dysfunction.
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4.2. Hsa-Cav1.3 and Hsa-miR-486-3p
Cav1.3 is a voltage-gated L-type Ca2+ channel that is important in the regulation of
the SN’s pacemaking function. When this channel is deactivated in mice, bradycardia
and sinoatrial arrhythmia are observed [21,22]. We have recently shown that hsa-miR-
486-3p is predicted to indirectly inhibit hsa-Cav1.3—with hsa-Cav1.3 being predicted to
have six binding sites for hsa-miR-486-3p [4]. Our luciferase assay experiment confirms
this prediction because the binding of hsa-miR-486-3p significantly reduces hsa-Cav1.3-
mediated bioluminescence (Figure 3).
4.3. Hsa-Cav3.1 and Hsa-miR-486-3p
Cav3.1 is a voltage-gated T-type Ca2+ channel that also plays a key role in regulating
the pacemaking function of the SN. Mangoni et al. (2006) demonstrated that the knockout
of Cav3.1 in mice led to the lack of transitory ICa,T current and slowed down the SN
pacemaker activity and AV conduction and reduced their heart rate [23]. We have recently
shown that hsa-miR-486-3p is predicted to indirectly inhibit hsa-Cav3.1—with Cav3.1
being predicted to have one binding site for hsa-miR-486-3p [4]. Our luciferase assay
experiment confirms this prediction because the binding of hsa-miR-486-3p significantly
reduces hsa-Cav3.1-mediated bioluminescence (Figure 3).
4.4. Hsa-TPSAB1 and Hsa-miR-486-3p
In the early phase of myocardial infarction, inflammatory cells migrate to the infarction
in order to aid cardiac repair [24]. It has been shown that a dysfunction of the immune
and inflammatory pathways may contribute to the development of various cardiovascular
diseases, including heart failure and arrhythmia [25,26]. Mast cells are involved in the
immune response pathways, and TPSAB1—the main tryptase isoenzyme that is expressed
in mast cells—plays a role in immunity [27].
Tryptase is the enzymatic activator of membrane protease-activated receptor 2 (PAR-
2)—a receptor that is expressed by cardiomyocytes [28]. These PAR-2 receptors are con-
nected to ERF kinases that mediate survival and hypertrophic signals. It could be assumed
that hsa-miR-486-3p suppresses the tryptase/PAR-2/ERK hypertrophy pathway in the SN,
preventing myocyte hypertrophy and therefore supporting the SN’s spindle-like neonatal-
like morphology. In addition, tryptase belong to the serine proteases family [29], and they
all have very conservative 3-UTRs with a unique secondary structure that is crucial to
mRNA stability.
We recently reported that hsa-TPSAB1 is significantly expressed in the adult human
SN and is predicted to be directly inhibited by hsa-miR-486-3p [10]. The function of TPSAB1
in the SN is unknown, but it is interesting to see its high expression in the SN. The binding
of hsa-miR-486-3p significantly reduces hsa-TPSAB1-mediated bioluminescence (Figure 5).
It is possible that the immune system is important for maintaining the pacemaking function
of the human SN. A high expression of hsa-miR-486-3p in the blood plasma of COVID-
19 patients [20] could result in the reduced expression of hsa-TPSAB1 and abnormal
functioning of immune cells in the SN. Based on this information, hsa-miR-486-3p could
be a promising target in the treatment of bradycardia that is experienced by COVID-19
patients [18,19].
The high expression of immune cells in the SN could slow down the development
of effective biological pacemakers. It has been supposed that immune cells contribute to
SN functioning. For example, Hu et al. (2014) reported that when an adenoviral vector of
TBX18 was delivered to a swine model of total heart block, it affected not only the heart
rhythm but also caused an immune response [30].
4.5. Hsa-miR-938
We have previously reported that hsa-miR-938 is one of the novel microRNAs that
is uniquely expressed in the human right atrium and is predicted to inhibit Cav1.3 [4].
Now, following our luciferase assay experiments, we observed a significant decrease in the
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luciferase activity of the mRNA encoding for Cav1.3 when hsa-miR-938 is added (Figure 4).
This observation suggests there is interaction between hsa-Cav1.3 and hsa-miR-938. The
function of this microRNA in the cardiovascular system is unknown, but this microRNA is
known to promote cell proliferation [31] and is linked to the development of gastric [32]
and pancreatic cancer [33].
5. Conclusions
With the growing occurrence of cardiovascular disease, particularly sinus node dys-
function (SND), as the global ageing population increases, it is important for us to identify
new therapeutic targets and to further understand the complex mechanisms that regulate
the SN’s pacemaking function. We hereby provide novel insights into the interacting be-
tween key microRNAs and ion channels and immune cell markers in H9C2 cells by further
exploring our previous predicted interactions (as described in Petkova et al. (2020) [4] and
Aminu et al. (2021) [10]). Using luciferase assay experiments, our observation of significant
reduction of luciferase activity suggests there is interaction between miR-486-3p and three
mRNAs (Cav1.3, Cav3.1, and TPSAB1) and between miR-938 and Cav1.3 mRNA. These
observations allow room for further explorations of how these microRNAs can be used for
ex vivo and in vivo experiments to study their effect on cardiac function/dysfunction, as
previously shown by Yanni et al., who injected an antimiR to miR-370 into heart failure
mice and restored HCN4 mRNA and protein expression in the SN, thus increasing the
beating rate [34], and recently by Petkova et al., who injected miR-486-3p into the rat SN
tissue and observed a reduced heart rate [4].
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